Table 3.
Association of different classes of previously used biologics with PASI 75 response.
| Week | Previous biologic use | ORa (95% CI) | p value |
|---|---|---|---|
| Week 12 | Biologicb naïve | 1.00 | |
| TNF-α inhibitor | 0.62 (0.05–14.27) | 0.710 | |
| IL-17 inhibitor | 0.19 (0.03–0.90) | 0.041 | |
| IL-12/23 inhibitor | 0.42 (0.16–1.06) | 0.071 | |
| Week 20 | Biologicb naïve | 1.00 | |
| TNF-α inhibitor | 0.17 (0.01–4.83) | 0.240 | |
| IL-17 inhibitor | 0.10 (0.02–0.55) | 0.010 | |
| IL-12/23 inhibitor | 0.39 (0.12–1.17) | 0.109 | |
| Week 28 | Biologicb naïve | 1.00 | |
| TNF-α inhibitor | 0.08 (0.00–2.42) | 0.107 | |
| IL-17 inhibitor | 0.03 (0.00–0.29) | 0.007 | |
| IL-12/23 inhibitor | 0.12 (0.01–0.75) | 0.056 |
CI, confidence interval; IL, interleukin; OR, odds ratio; PASI, Psoriasis Area and Severity Index; TNF-α, tumour necrosis factor-α.
a
Univariate analysis.
b
Biologics included in the study: TNF-α inhibitor (etanercept and adalimumab), IL-12/23 inhibitor (ustekinumab), IL-17 inhibitor (secukinumab and ixekizumab), and IL-23 inhibitor (risankizumab).